DOCSLIB.ORG

Bioactive Compound Library Plus (96-Well)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioactive Compound Library Plus (96-Well) • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com Bioactive Compound Library Plus (96-well) Product Details: Catalog Number: CS-L001P Formulation: A collection of 13195 bioactive compounds supplied as pre-dissolved Solutions or Solid Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: CS-L001P-Part A-1 1 2 3 4 5 6 7 8 9 10 11 12 SKF-96365 Fumarate MRT68921 a Empty (hydrochlorid ML162 ML-210 hydratase-IN- (dihydrochlori Vonoprazan Peretinoin Ufenamate SR-3029 CBR-5884 Empty e) 1 de) (1R,2R)-2- 2-PCCA HLCL-61 b Empty PCCA (hydrochlorid Mivebresib AZD0156 BAY-876 BAY1125976 BAY-1436032 Tomivosertib LY3177833 (hydrochlorid Empty (hydrochlorid e) e) Ro 41-1049 c Empty PQR620 (hydrochlorid AT-130 Bay 41-4109 PD 117519 NSC 663284 MK-4101 YYA-021 Faropenem Bromobimane Empty e) (racemate) daloxate Flavopiridol 2- 9- (Z)-9- Dolutegravir d Empty Flavopiridol (Hydrochlorid (Dimethylami NPS-2143 Propenyladen Propenyladen SNS-032 intermediate- Semagacesta Ko 143 Empty e) no)acetaldeh ine ine 1 t AT2 receptor Mitoquinone JNJ- e Empty KNK437 GLX351322 agonist C21 TA-01 TA-02 (mesylate) BW-A 78U AZD-5438 Tubercidin 17203212 Empty N-[(4- Taranabant f Empty Taranabant Aminophenyl) GSK481 Taranabant ((1R,2R)stere R547 Pipequaline Pirozadil PAP-1 4-IBP Empty methyl]adeno (racemate) oisomer) Toll-like g Empty E 2012 SDZ-MKS BAPTA SCH 546738 receptor Delpazolid DSM265 GSK- Varenicline SAR-020106 Empty 492 modulator 2881078 Pyrroloquinoli Varenicline h Empty Pyrroloquinoli ne quinone HUHS015 (Hydrochlorid SMER28 A-196 TPEN CP21R7 HC-067047 Varenicline Empty ne quinone (disodium e) (Tartrate) Plate layout: CS-L001P-Part A-2 1 2 3 4 5 6 7 8 9 10 11 12 Biotin DL-3- a Empty EAI045 Hydrazide Indolylglycine RSL3 GSK6853 AM-2394 CZ415 Calpeptin SANT-1 ME0328 Empty SKF89976A ML133 b Empty A-205804 E 64c (hydrochlorid Aloxistatin (hydrochlorid IQ-1S (free DREADD GSK591 Madrasin SZL P1-41 Empty e) e) acid) agonist 21 Rho-Kinase- Tyrosine c Empty CI-1044 Trifarotene IN-1 Org41841 Naminidil Mifobate Nutlin-3a KW-8232 9-amino-CPT kinase-IN-1 Empty SRI-011381 d Empty MCHR1 PCI-33380 AC260584 WWL70 GSK583 M2I-1 GNE-495 PK14105 (hydrochlorid EPI-001 Empty antagonist 2 e) AQ-13 MELK-8a DMCM e Empty CA-074 BI-7273 BI-9564 dihydrochlorid CL-82198 MS049 Remetinostat Lu AF21934 (hydrochlorid (hydrochlorid Empty methyl ester e e) e) Isavuconazon Diroximel TPO agonist Nigericin f Empty Quiflapon MRK-016 (RS)-MCPG ium (sulfate) fumarate Valrocemide A 922500 1 (sodium salt) FPTQ Empty SHP099 g Empty BH3I-1 NKL 22 Brevianamide SHP099 (hydrochlorid (S)- NVP- F16 SQ22536 PF-04979064 Empty F e) ML753286 BAW2881 K-604 h Empty Nevanimibe dihydrochlorid Pactimibe Pactimibe CFMTI Ro 67-7476 JNJ16259685 GNF-6231 PHCCC FCCP Empty hydrochloride e (sulfate) Plate layout: CS-L001P-Part A-3 1 2 3 4 5 6 7 8 9 10 11 12 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com LY2365109 a Empty MLi-2 Linaprazan UKI-1 (hydrochlorid BFH772 Odanacatib CPI-455 KDM5-IN-1 Imazamox CAN508 Empty e) gamma- Empty CCF642 IMR-1 IMR-1A PACMA 31 PD-161570 Cadazolid HA15 secretase WYE-132 Treprostinil Empty b modulator 1 αvβ1 integrin- TM5275 c Empty Paquinimod IN-1 (TFA) (sodium) AEE788 TCS-OX2-29 HO-3867 CGP 25454A ZL006 IC87201 GSK3179106 Empty REV7/REV3L d Empty Plerixafor C29 PTP1B-IN-2 TPI-1 -IN-1 NSC781406 Esaxerenone ZYZ-488 Visomitin CPI-637 Empty Rilmenidine e Empty A-804598 BTTAA TAK-243 Bay 59-3074 TBHQ (hemifumarat Rilmenidine Fisogatinib BP-1-102 SH5-07 Empty e) (phosphate) Tyrphostin f Empty FT011 GSK2256098 AG 528 M2698 CID5721353 GLPG0187 Avadomide ITSA-1 NPS-1034 RAF709 Empty Benzophenon Benzenepent GSK484 g Empty etetracarboxyl acarboxylic (hydrochlorid T-26c NVS-PAK1-1 Aprepitant GKI-1 FMK 9a ML385 LRE1 Empty ic acid Acid e) Nanchangmy Sp-cAMPS h Empty XMU-MP-1 AN2718 cin Dianemycin PD150606 Maropitant (sodium salt) DprE1-IN-2 CD437 IDE1 Empty Plate layout: CS-L001P-Part A-4 1 2 3 4 5 6 7 8 9 10 11 12 D-α- GSK-LSD1 a Empty DTP3 DTP3 (TFA) Golgicide A Golgicide A-2 Golgicide A-1 INH6 Hydroxyglutar FLLL32 BAPTA-AM (dihydrochlori Empty ic acid de) Cyclo(RGDyK Empty GSK621 (S)-Crizotinib MSDC 0160 meso- Tie2 kinase SecinH3 Abscisic acid Tempol Flopropione ) Empty b Erythritol inhibitor 1 (trifluoroaceta Cl-amidine c Empty SGC2085 Necrosulfona (hydrochlorid Acriflavine NH125 AGK2 Ferrostatin-1 Asaraldehyde CORM-3 Ribitol Empty mide e) VU0364770 d Empty (-)-(S)-Equol (±)-Equol Davercin Splitomicin D-Glutamine VU0364770 (hydrochlorid SirReal2 Nicaraven Spiramycin Empty e) Sodium Landiolol e Empty stibogluconat AS1842856 Saponins Urolithin A BGG463 HJC0152 (hydrochlorid BMS453 4-P-PDOT CaCCinh-A01 Empty e hydrochloride e) BMS-986020 Roflumilast N- f Empty T16Ainh-A01 AS1517499 Hispidin BMS-986020 (sodium) BVT948 WNK463 APS-2-79 FGFR4-IN-1 oxide Empty AZD5153 (6- Empty Ticagrelor Axitinib Hydroxy-2- Didesethyl Fosfluconazol Mycro 3 Y-33075 L002 SR59230A LM22A-4 Empty g naphthoic chloroquine e Y-33075 h Empty JTE-013 CGS 15943 GSK2837808 MS-444 U93631 GNF-PF-3777 ML390 Propyl (dihydrochlori NOD-IN-1 Empty A pyrazole triol de) Plate layout: CS-L001P-Part A-5 1 2 3 4 5 6 7 8 9 10 11 12 Lin28-let-7a a Empty antagonist 1 SYP-5 TPOP146 Pipamperone NSC632839 Y-27632 D-AP5 Eganelisib HT-2157 BRD-6929 Empty Histone b Empty GSK2193874 BM212 GNE-272 AM-2099 BMT-145027 GSK9311 Cambinol 4E2RCat Acetyltransfer C 87 Empty ase Inhibitor II (1α,1'S,4β)- GNE-140 c Empty ML348 ML349 RA190 TPCA-1 Lanabecestat Lanabecestat S63845 (racemate) (R)-GNE-140 (S)-GNE-140 Empty Norverapamil d Empty AS8351 STF-62247 PSB-12379 CXD101 (hydrochlorid STAT3-IN-1 Ritlecitinib (2R,5S)- KR-33493 FUBP1-IN-1 Empty e) Ritlecitinib L-AP4 (-)-Bicuculline e Empty Toxoflavin HTHQ YL0919 PCC0208009 Setogepram Rimacalib (monohydrate (methobromid gamma-DGG 2-PMPA Empty (sodium salt) ) e) Pirmenol f Empty CHS-828 Ciliobrevin A NSC23005 URB602 SR12813 (hydrochlorid Teglarinad Hypotaurine Kynurenic Quinolinic Empty (sodium) e) (chloride) acid acid Isoguvacine 7- 7- (RS)-AMPA g Empty D-Serine Guvacine GS-6201 (hydrochlorid Chlorokynure Chlorokynure (monohydrate Rbin-1 Futibatinib 3-AP Empty hydrochloride e) nic acid nic acid ) OABK Piperoxan h Empty (hydrochlorid BGP-15 NCB-0846 YM-58483 UNC3866 Antibiotic-5d GS-444217 JQEZ5 (hydrochlorid IWP-O1 Empty e) e) Plate layout: CS-L001P-Part A-6 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Tel: 732-484-9848 Fax: 888-484-5008 Email: [email protected] • Bioactive Molecules • Building Blocks • Intermediates www.ChemScene.com 1 2 3 4 5 6 7 8 9 10 11 12 TAK-659 a Empty PCO371 BRCA1-IN-2 (hydrochlorid Navitoclax ABX464 WT-161 KRIBB11 PF-1355 Bisantrene GGTI298 Empty e) ONO- (R)- b Empty GCN2-IN-1 Zibotentan TUG-891 7300243 Acelarin BAY1082439 Simurosertib Simurosertib CD80-IN-3 MX69 Empty Norbinaltorphi (±)- W-7 c Empty SAR-20347 OGT 2115 ML364 CDD3505 CDD3506 mine Acetylcarnitin (hydrochlorid ML-9 MY-5445 Empty dihydrochlorid e (chloride) e) Cinanserin ATM-3507 d Empty DPCPX CCCP (hydrochlorid Conduritol B CEP-40783 VH-298 (trihydrochlori Olcegepant Beaucage CYM-5520 Empty e) epoxide de) reagent 2,4-Diamino- Dilazep Diphenylenei Adenosine 5′- e Empty 6- Flurofamide (dihydrochlori (E)-AG 99 odonium 4F 4PP Spiramide diphosphorib TB5 HA-100 Empty hydroxypyrimi de) chloride (oxalate) ose (sodium) L-NIO f Empty (dihydrochlori FG 7142 10074-G5 NPPB MK-8617 Nrf2-IN-1 CCT251236 GSK 4027 GSK4028 ZINC1346675 Empty de) 1 ZK756326 AR-M g Empty RIPA-56 LOM612 Choline Sarcosine (dihydrochlori 1000390 Q203 AG-494 D-erythro- Src Inhibitor 1 Empty (bitartrate) de) (hydrochlorid Sphingosine Kinetin L-690330 h Empty NQ301 riboside Brensocatib TOFA Y-26763 Monastrol Salermide (hydrate) LY294002 NSC 228155 Empty Plate layout: CS-L001P-Part A-7 1 2 3 4 5 6 7 8 9 10 11 12 Acetylcholine a Empty SKL2001 (iodide) CeMMEC13 RHPS4 AS-605240 KYA1797K Importazole Ocaperidone MK-8998 PD-1-IN-17 Empty (2- SB-224289 b Empty IC-87114 Hydroxypropy (hydrochlorid AR7 TG100-115 PF-06840003 GLP-1R EED226 666-15 TP-3654 Empty l)-β- e) Antagonist 1 PI-103 c Empty Bicyclomycin PNU-74654 Dansyl TGX-221 PGMI-004A SF2523 PI-103 (Hydrochlorid 3-Bromo-7- 2- Empty benzoate glutathione e) nitroindazole Iodomelatonin Naltrindole Tin- d Empty (hydrochlorid Tesmilifene Filibuvir C2 Ceramide T807 JNJ- Vorapaxar Ecteinascidin GSK682753A protoporphyri Empty e) (fumarate) 39758979 770 n IX SB-203186 e Empty GJ103 Asenapine UK-371804 Org-26576 BI 689648 Silodosin (hydrochlorid Tiotidine DHBP Agmatine Empty (sodium salt) e) (dibromide) (sulfate) Oxotremorine AM-92016 f Empty (sesquifumar XMD16-5 ZINC0088152 RPI-1 L-732138 (hydrochlorid Luzindole ODQ YKL-5-124 YKL-5-124 Empty ate) 4 e) (TFA) Milademetan g Empty Barasertib- CCR2 S1p receptor (tosylate CHMFL-BMX- Barasertib STK16-IN-1 WAY-200070 GDC-0326 BAR502 Empty HQPA antagonist 3 agonist 1 hydrate) 078 EMT inhibitor- (R)-VU h Empty BAR501 1 Vadadustat Thiomyristoyl ST034307 ZM-447439 VU 6008667 6008667 HCH6-1 DMU2105 Empty Plate layout: CS-L001P-Part A-8 1 2 3 4 5 6 7 8 9 10 11 12 Dihydrexidine Veliparib a Empty DMU2139 Veliparib Iberdomide FK614 TPPU Pan-RAS-IN- PD-166866 Paprotrain (hydrochlorid (dihydrochlori Empty 1 e) de) Cirazoline AHN 1-055 b Empty (hydrochlorid Cilostamide (hydrochlorid Phenylbiguan RS 17053 ZD7288 L-741626 R-IMPP 8-M-PDOT Hesperin Empty e) e)
Load more

Recommended publications
  • Roger Lee Papke Box 100267 JHM Health Science Center Gainesville, Florida 32610
    CURRICULUM VITAE Roger Lee Papke DEPARTMENT OF PHARMACOLOGY AND THERAPEUTICS UNIVERSITY OF FLORIDA SCHOOL OF MEDICINE Box 100267 J.H.M. Health Science Center Gainesville, Florida 32610 (352) 392-4712, FAX (352) 392-9696 [email protected] BIOGRAPHICAL DATA: Born: October 12, 1953, Kenmore, New York Married: December 24, 1980 to Clare Stokes Citizenship: U. S. A. EDUCATION: Starpoint Central School Pendleton, N. Y. Primary and Secondary N.Y.S. Regents Diploma 1971 New York University Washington Square College of Arts and Sciences 1971 - 1975 Majors in Biology and Classical Civilization Bachelor of Arts awarded May 1975 New York University Graduate school of Arts and Sciences 1975 - 1976 Thesis advisor: Dr. Fleur L. Strand Thesis title: An Alpha Adrenergic Response of Cardiac Muscle at an Alkaline pH Master of Science awarded May 1976 Cornell University Graduate School of Arts and Science 1976-1979: Section of Physiology Graduate Research Assistant in Reproductive Physiology Advisor: Dr. William Hansel Research topic: The endocrine control of delayed implantation in mink Cornell University Graduate School of Arts and Science 1979-1986: Section of Neurobiology and Behavior Thesis Advisor: Dr. Robert Oswald Primary research topic: Pharmacology of nicotinic acetylcholine receptors Thesis Title: The Gating of Single Channel Currents Through the Nicotinic Acetylcholine Receptors of BC3H-1 Cells: Effects of Agonists and Allosteric Ligands Ph.D. conferred January 1987 ACADEMIC APPOINTMENTS: 1987 Postdoctoral Research Associate: Department of Pharmacology,
    [Show full text]
  • Substances That Target Tumor Metabolism
    Biomedical Research 2011; 22 (2): 132-166 1181_On the metabolic origin of cancer: substances that target tumor metabolism. Maurice Israël 1 and Laurent Schwartz 2 1Biorebus 38 rue de Bassano 75008 Paris ; and 2 Av Aristide Briand 91440 Bures sur Yvette. France. 2LIX : Ecole Polytechnique Palaiseau France ; and Hôpital Pitié- Salpêtrière, service de radiothérapie, 75013 Paris. Abstract. Work from our group and others clearly suggest the key role of altered metabolism in cancer. The goal of this review is to summarize current knowledge on cancer metabolism, draw hy- pothesis explaining metabolic alterations and associated gene changes. Most importantly, we indicate a list of possible pharmacological targets. In short, tumor metabolism displays mixed glycolysis and neoglucogenesis features; most glycolitic enzymes are activate, but the pyruvate kinase and the pyruvate deshydrogenase are inhibited. This would result from an activation of their specific kinases, or from the inactivation of phosphatases, such as PP2A, regulated by me- thylation. In parallel, the phosphatase failure would enhance “tyrosine kinase receptor” signals, as occurs with oncogenes. Such signaling pathways are similar to those activated by insuline, or IGF- Growth hormone; they control mitosis, cell survival, carbohydrate metabolism. If for some reason, their regulation fails (oncogenes, PP2A methylation deficit, enhanced kinases…) a typical tumor metabolism starts the carcinogenic process. We also describe changes in the citric acid- urea cycles, polyamines, and show how body stores feed tumor metabolic pathways above and below “bottlenecks” resulting from wrongly switched enzymes. Studying the available lit- erature, we list a number of medications that target enzymes that are essential for tumor cells.
    [Show full text]
  • Differential Effects of Alkaloids on Memory in Rodents
    www.nature.com/scientificreports OPEN Diferential efects of alkaloids on memory in rodents Patrick M. Callahan1,2, Alvin V. Terry Jr.1,2, Manuel C. Peitsch3, Julia Hoeng3* & Kyoko Koshibu3* Nicotinic acetylcholine receptors (nAChRs) play a critical role in the neuropharmacology of learning and memory. As such, naturally occurring alkaloids that regulate nAChR activity have gained interest for understanding and potentially improving memory function. In this study, we tested the acute efects of three known nicotinic alkaloids, nicotine, cotinine, and anatabine, in suppressing scopolamine-induced memory defcit in rodents by using two classic memory paradigms, Y-maze and novel object recognition (NOR) in mice and rats, respectively. We found that all compounds were able to suppress scopolamine-induced spatial memory defcit in the Y-maze spontaneous alternation paradigm. However, only nicotine was able to suppress the short-term object memory defcit in NOR, despite the higher doses of cotinine and anatabine used to account for their potential diferences in nAChR activity. These results indicate that cotinine and anatabine can uniquely regulate short-term spatial memory, while nicotine seems to have more robust and general role in memory regulation in rodents. Thus, nAChR-activating alkaloids may possess distinct procognitive properties in rodents, depending on the memory types examined. Te cholinergic system of the brain is a critical regulator of attention, memory, and higher-order cognitive processing, and its defcits are central to the etiology of dementia1. As such, nicotinic acetylcholine receptors (nAChRs) have gained much interest as a target of drug development 2. Neuronal nAChRs are pentameric pro- teins composed of various combinations of α (α2–α9) and β (β2–β4) nAChR subunits, diferentially expressed throughout the nervous system.
    [Show full text]
  • Domains: 1. Optimizing Medication Use, Using Front- and Back Office Strategies 2
    A SUPPLEMENTARY TABLES Table S1: Domains and themes in the action plan of the Belgian Government (2015-2020) Domains: 1. Optimizing medication use, using front- and back office strategies 2. Continuity of pharmacotherapy in light of transmural care 3. Scientific skills of the hospital pharmacist 4. Transfer of information to and communication with the patient Themes: 2015: anchoring the minimal conditions for the application of clinical pharmacy 2016: development of a structured method for the anamnesis, registration and communication of the medication on admission and discharge 2017: application of clinical pharmacy for specific therapies 2018: application of risk screening for patient groups 2019: application of risk screening for medication groups or pathologies 2020: evaluation of the development of clinical pharmacy in the Belgian hospitals and evaluation of the action plan 2015-2020 Table S2: Anatomical and therapeutic classes of the drugs involved in the discrepancies detected after medication reconciliation n (%) Example(s) of discrepancy Gastro-intestinal system 43 (35.2%) antacids 6 O: antacid PRN antihistaminics 1 O: ranitidine 150 mg 1 pd proton pump inhibitors 5 O: pantoprazole 20 mg 1 pd propulsives 3 O: domperidone PRN; N: alizapride laxatives 9 O: macrogol PRN or 1 pd, bisacodyl PRN or 1 pd antipropulsives 2 O: loperamide 1 pd probiotics 1 O: frequent need for probiotics antidiabetics 1 D: dose repaglinide unknown multivitamins 5 O: multivitamins 1 pd vitamin D 5 O: vitamin D 1 per week vitamin B 2 N: vitamin B complex
    [Show full text]
  • Multifaceted Physiological Roles of Adiponectin in Inflammation And
    International Journal of Molecular Sciences Review Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases Hyung Muk Choi 1, Hari Madhuri Doss 1,2 and Kyoung Soo Kim 1,2,* 1 Department of Clinical Pharmacology and Therapeutics, Kyung Hee University School of Medicine, Seoul 02447, Korea; [email protected] (H.M.C.); [email protected] (H.M.D.) 2 East-West Bone & Joint Disease Research Institute, Kyung Hee University Hospital at Gangdong, Gandong-gu, Seoul 02447, Korea * Correspondence: [email protected]; Tel.: +82-2-961-9619 Received: 3 January 2020; Accepted: 10 February 2020; Published: 12 February 2020 Abstract: Adiponectin is the richest adipokine in human plasma, and it is mainly secreted from white adipose tissue. Adiponectin circulates in blood as high-molecular, middle-molecular, and low-molecular weight isoforms. Numerous studies have demonstrated its insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects. Additionally, decreased serum levels of adiponectin is associated with chronic inflammation of metabolic disorders including Type 2 diabetes, obesity, and atherosclerosis. However, recent studies showed that adiponectin could have pro-inflammatory roles in patients with autoimmune diseases. In particular, its high serum level was positively associated with inflammation severity and pathological progression in rheumatoid arthritis, chronic kidney disease, and inflammatory bowel disease. Thus, adiponectin seems to have both pro-inflammatory and anti-inflammatory effects. This indirectly indicates that adiponectin has different physiological roles according to an isoform and effector tissue. Knowledge on the specific functions of isoforms would help develop potential anti-inflammatory therapeutics to target specific adiponectin isoforms against metabolic disorders and autoimmune diseases.
    [Show full text]
  • In Vitro Testicular Toxicity Models : Opportunities for Advancement Via Biomedical Engineering Techniques
    Erschienen in: Alternatives to Animal Experimentation : ALTEX ; 30 (2013), 3. - S. 353-377 http://dx.doi.org/10.14573/altex.2013.3.353 t4 Report* In Vitro Testicular Toxicity Models: Opportunities for Advancement via Biomedical Engineering Techniques Louise Parks Saldutti 1, Bruce K. Beyer 2, William Breslin 3, Terry R. Brown 4, Robert E. Chapin 5, Sarah Campion 5, Brian Enright 6, Elaine Faustman 7, Paul M. D. Foster 8, Thomas Hartung 9, William Kelce 10, James H. Kim 11, Elizabeth G. Loboa 12, Aldert H. Piersma 13, David Seyler 14, Katie J. Turner 15, Hanry Yu 16, Xiaozhong Yu 17, and Jennifer C. Sasaki 18 1 2 Department of Development & Reproduction, Merck & Co., West Point, PA, USA; Department of Disposition, Safety 3 and Animal Research – Preclinical Safety, Sanofi U.S. Inc., Bridgewater, NJ, USA; Eli Lilly and Company, Lilly Research 4 Laboratories, Indianapolis, IN, USA; Department of Biochemistry & Molecular Biology, Johns Hopkins Bloomberg School of 5 Public Health, Baltimore, MD, USA; Pfizer Inc., Global R&D, Developmental and Reproductive Toxicology Group, Groton, 7 CT, USA; 6AbbVie Inc., North Chicago, IL, USA; University of Washington, Department of Environmental and Occupational 8 Health Sciences, Institute for Risk Analysis and Risk Communication, Seattle, WA, USA; National Toxicology Program, National Institutes of Environmental Health Sciences, National Institute of Health, Department of Health and Human Services, 9 Research Triangle Park, NC, USA; Johns Hopkins University, Bloomberg School of Public Health, Center for
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Adiporon, an Orally Active, Synthetic Agonist of Adipor1 and Adipor2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice
    molecules Article AdipoRon, an Orally Active, Synthetic Agonist of AdipoR1 and AdipoR2 Receptors Has Gastroprotective Effect in Experimentally Induced Gastric Ulcers in Mice Hubert Zatorski 1,2, Maciej Salaga 1 , Marta Zieli ´nska 1, Kinga Majchrzak 1, Agata Binienda 1 , Radzisław Kordek 3, Ewa Małecka-Panas 2 and Jakub Fichna 1,4,* 1 Department of Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] (H.Z.); [email protected] (M.S.); [email protected] (M.Z.); [email protected] (K.M.); [email protected] (A.B.) 2 Department of Digestive Tract Diseases, Medical University of Lodz, 93-281 Lodz, Poland; [email protected] 3 Department of Pathology, Medical University of Lodz, 92-215 Lodz, Poland; [email protected] 4 Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland * Correspondence: jakub.fi[email protected]; Tel.: +48-42-272-57-07 Citation: Zatorski, H.; Salaga, M.; Abstract: Introduction: Adiponectin is a hormone secreted by adipocytes, which exhibits insulin- Zieli´nska,M.; Majchrzak, K.; sensitizing and anti-inflammatory properties and acts through adiponectin receptors: AdipoR1 and Binienda, A.; Kordek, R.; AdipoR2. The aim of the study was to evaluate whether activation of adiponectin receptors AdipoR1 Małecka-Panas, E.; Fichna, J. and AdipoR2 with an orally active agonist AdipoRon has gastroprotective effect and to investigate AdipoRon, an Orally Active, the possible underlying mechanism. Methods: We used two well-established mouse models of Synthetic Agonist of AdipoR1 and gastric ulcer (GU) induced by oral administration of EtOH (80% solution in water) or diclofenac AdipoR2 Receptors Has (30 mg/kg, p.o.).
    [Show full text]
  • Download Drug Labels List
    Syringe Labelling System Price Per Label Description/Drug Name Item No. Quanitiy Per Pack Pack Abciximab 99801 2 x 500 roll's £6.30 Abidec 100602 2 x 500 roll's £6.30 Acepromazine 99802 2 x 500 roll's £6.30 Acetazolamide 99803 2 x 500 roll's £6.30 Acetylcholine 99804 2 x 500 roll's £6.30 Acetylcysteine 99805 2 x 500 roll's £6.30 Acetylsalicylic Acid 99806 2 x 500 roll's £6.30 Aciclovir 99807 2 x 500 roll's £6.30 ACP/Buprenorphine 100208 2 x 500 roll's £6.30 Actrapid Insulin 99808 2 x 500 roll's £6.30 Adenosine 99809 2 x 500 roll's £6.30 Adrenaline (Top Half Black, Bottom Violet, Violet Text) 99810 2 x 500 roll's £6.30 Adrenaline/Epinephrine 99811 2 x 500 roll's £6.30 Albumin Solution 99812 2 x 500 roll's £6.30 Alchol 99813 2 x 500 roll's £6.30 Alemtuzmab 99814 2 x 500 roll's £6.30 ALERT 100243 2 x 500 roll's £6.30 Alfaxalone 99815 2 x 500 roll's £6.30 Alfentanil 99816 2 x 500 roll's £6.30 Alfentanil 99817 2 x 500 roll's £6.30 Alteplase 99818 2 x 500 roll's £6.30 Amikacin 99819 2 x 500 roll's £6.30 Aminophylline 99820 2 x 500 roll's £6.30 Amiodarone 100194 2 x 500 roll's £6.30 Amoxicillin 100195 2 x 500 roll's £6.30 Amphotericin 99821 2 x 500 roll's £6.30 Ampicillin 99822 2 x 500 roll's £6.30 Antibiotic 99823 2 x 500 roll's £6.30 Anticoagulant 99824 2 x 500 roll's £6.30 Antifungal 100228 2 x 500 roll's £6.30 Antiseptic 99825 2 x 500 roll's £6.30 Aprotinin 99826 2 x 500 roll's £6.30 Aqueous Iodine 99827 2 x 500 roll's £6.30 Arterial 100259 2 x 500 roll's £6.30 Arterial ( Line Label - White with Red Writing) 100176 2 x 500 roll's £6.30 Arterial
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Natural Products As Alternative Choices for P-Glycoprotein (P-Gp) Inhibition
    Review Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition Saikat Dewanjee 1,*, Tarun K. Dua 1, Niloy Bhattacharjee 1, Anup Das 2, Moumita Gangopadhyay 3, Ritu Khanra 1, Swarnalata Joardar 1, Muhammad Riaz 4, Vincenzo De Feo 5,* and Muhammad Zia-Ul-Haq 6,* 1 Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India; [email protected] (T.K.D.); [email protected] (N.B.); [email protected] (R.K.); [email protected] (S.J.) 2 Department of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 3 Department of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India; [email protected] 4 Department of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan; [email protected] 5 Department of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy 6 Environment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan * Correspondence: [email protected] (S.D.); [email protected] (V.D.F.); [email protected] (M.Z.-U.-H.) Academic Editor: Maria Emília de Sousa Received: 11 April 2017; Accepted: 15 May 2017; Published: 25 May 2017 Abstract: Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc.
    [Show full text]